Antibacterial Resistance Leadership Group 2.0: Back to Business.

Journal Article (Journal Article)

In December 2019, the Antibacterial Resistance Leadership Group (ARLG) was awarded funding for another 7-year cycle to support a clinical research network on antibacterial resistance. ARLG 2.0 has 3 overarching research priorities: infections caused by antibiotic-resistant (AR) gram-negative bacteria, infections caused by AR gram-positive bacteria, and diagnostic tests to optimize use of antibiotics. To support the next generation of AR researchers, the ARLG offers 3 mentoring opportunities: the ARLG Fellowship, Early Stage Investigator seed grants, and the Trialists in Training Program. The purpose of this article is to update the scientific community on the progress made in the original funding period and to encourage submission of clinical research that addresses 1 or more of the research priority areas of ARLG 2.0.

Full Text

Duke Authors

Cited Authors

  • Chambers, HF; Evans, SR; Patel, R; Cross, HR; Harris, AD; Doi, Y; Boucher, HW; van Duin, D; Tsalik, EL; Holland, TL; Pettigrew, MM; Tamma, PD; Hodges, KR; Souli, M; Fowler, VG

Published Date

  • August 16, 2021

Published In

Volume / Issue

  • 73 / 4

Start / End Page

  • 730 - 739

PubMed ID

  • 33588438

Pubmed Central ID

  • PMC8366825

Electronic International Standard Serial Number (EISSN)

  • 1537-6591

Digital Object Identifier (DOI)

  • 10.1093/cid/ciab141


  • eng

Conference Location

  • United States